公开(公告)号：US12287324B2

公开(公告)日：2025-04-29

申请号：US16962917

申请日：2019-01-14

Applicant: University of North Texas Health Science Center at Fort Worth

Inventor： Sid E. O'Bryant

IPC: G01N33/50 ,  G01N33/68

Abstract: The present invention includes a method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) or an acetylcholinesterase (AChE) inhibitor drug comprising: obtaining a blood or serum sample from the patient; determining the presence of a proinflammatory endophenotype in the blood or serum sample of the patient; using the proinflammatory endophenotype to detect treatment response (a responder, a stable, a non-responder or an adverse responder); and treating the patient with the NSAID or the AChE inhibitor if the patient is in the responder or the stable treatment response phenotype group; or preventing a treatment with the NSAID or the AChE inhibitor if the patient is a non-responder or an adverse responder.

公开(公告)号：US20240173256A1

公开(公告)日：2024-05-30

申请号：US18522220

申请日：2023-11-28

Applicant: University of North Texas Health Science Center

Inventor： Nirupama SABNIS ,  Andras LACKO ,  Rafal FUDALA

IPC: A61K9/107 ,  A61K31/704 ,  A61K47/12 ,  A61K47/24 ,  A61K47/28 ,  A61K47/42 ,  A61K51/12

CPC classification number: A61K9/1075 ,  A61K31/704 ,  A61K47/12 ,  A61K47/24 ,  A61K47/28 ,  A61K47/42 ,  A61K51/1227

Abstract: The present disclosure is directed to an SR-B1-targeting nanomicelle and compositions, methods of synthesis and methods of use thereof. The nanomicelle may be an HDL-mimetic drug delivery system and may be cross-linked with DSS. The composition may contain a therapeutic agent with the ability to treat cancers, especially sarcomas.

公开(公告)号：US20240159776A1

公开(公告)日：2024-05-16

申请号：US18549183

申请日：2022-03-07

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Inventor： O'Bryant Sid E.

IPC: G01N33/68 ,  A61K45/06 ,  G01N33/92

CPC classification number: G01N33/6896 ,  A61K45/06 ,  G01N33/6869 ,  G01N33/92 ,  G01N2333/525 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/5418 ,  G01N2333/5428 ,  G01N2333/605 ,  G01N2333/62 ,  G01N2333/745 ,  G01N2800/2814 ,  G01N2800/56

Abstract: The present invention includes methods for detecting neurodegeneration and treating a subject that is of Mexican American or non-Hispanic white origin, the method comprising: obtaining a blood, plasma or serum sample; determining ethnicity of the subject; measuring one or more biochemical biomarkers; or measuring one or more protein biomarkers, or measuring both biochemical biomarkers and protein biomarkers; comparing the level of expression from the sample with a statistical sample representative of the subject of Mexican American or of non-Hispanic white origin, suspected of having neurodegeneration; and treating the subject with a treatment that targets neurodegeneration or neuronal injury, wherein the neurodegeneration or neuronal injury is measured by [18F]-fluorodeoxyglucose-PET, structural MRI, or CSF total tau.

公开(公告)号：US20240131113A1

公开(公告)日：2024-04-25

申请号：US18547382

申请日：2022-02-22

Applicant: The Regents of the University of Colorado, A Body Corporate ,  The University of North Texas Health Science Center at Fort Worth

Inventor： Ram H. NAGARAJ ,  Rooban B. NAHOMI ,  Dorota L. STANKOWSKA

IPC: A61K38/17 ,  A61K9/00 ,  A61K47/64 ,  A61P27/06 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A61K9/0019 ,  A61K9/0048 ,  A61K47/64 ,  A61P27/06 ,  C07K7/06 ,  C07K14/47

Abstract: Peptide-based therapies for a retinal disease, injury, or condition in a subject involve administering to the subject a pharmaceutical composition containing at least one peptide derived from a heat shock protein, including Hsp20 and αB-crystallin. The administered peptides may be acetylated and/or conjugated to a cell-penetrating peptide. Administration of the peptides may reduce or prevent the loss of at least one retinal cell type, including retinal ganglion cells and retinal endothelial cells. The loss of such cells causes retinal damage and loss of eyesight in patients afflicted with an ocular condition. The pharmaceutical compositions may be administered intravitreally using an administration device. A single injection may be therapeutically sufficient for treating various ocular conditions.

公开(公告)号：US20240117445A1

公开(公告)日：2024-04-11

申请号：US18263914

申请日：2022-03-16

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Inventor： Jianye Ge ,  Bruce Budowle ,  Sammed Mandape ,  Jonathan King

IPC: C12Q1/6888

CPC classification number: C12Q1/6888 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The present invention includes a method for determining nucleic acid contributors to a sample from nucleic acids by determining one or more macrohaplotypes, comprising the steps of: obtaining or having obtained a sample; designing macrohaplotypes to obtain two or more markers selected from Short Tandem Repeat (STR), Single Nucleotide Polymorphisms (SNPs), Insertion-Deletions (Indels), or combinations thereof; generating amplicons or obtaining a sequence of amplicons from the sample from a paternal, maternal, or both chromosomes; sequencing the amplified products with LRS technologies; calling the haplotype variants of the sequence data; calculating from the one or more macrohaplotypes one or more nucleic acid contributors to the biological sample or specimen; comparing the one or more macrohaplotypes to a reference or known macrohaplotype profile from a subject suspected of contributing nucleic acids to the sample; and identifying a number of contributors to the sample.

公开(公告)号：US20230357737A1

公开(公告)日：2023-11-09

申请号：US18201537

申请日：2023-05-24

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER

Inventor： Jin LIU ,  Zhicheng ZUO ,  Yu-Chieh WANG

IPC: C12N9/22 ,  G16B15/00 ,  G16B5/00 ,  G06F30/20 ,  C12N15/11 ,  G06F17/16

CPC classification number: C12N9/22 ,  G16B15/00 ,  G16B5/00 ,  G06F30/20 ,  C12N15/11 ,  G06F17/16 ,  G06F2111/10

Abstract: Certain embodiments are directed to modified or variant Cas9 proteins, and/or methods of using the same.

公开(公告)号：US20220162701A1

公开(公告)日：2022-05-26

申请号：US17430748

申请日：2020-02-14

Applicant: University of North Texas Health Science Center at Fort Worth ,  Board of Regents, The University of Texas System

Inventor： Sid E. O'Bryant ,  Robert C. Barber ,  Guanghua Xiao ,  Dwight German

IPC: C12Q1/6883 ,  G16B20/00 ,  G16B40/20

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNFα, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, α-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

公开(公告)号：US20210215720A1

公开(公告)日：2021-07-15

申请号：US17193907

申请日：2021-03-05

Applicant: University of North Texas Health Science Center at Fort Worth

Inventor： Sid E. O'Bryant

IPC: G01N33/68

Abstract: The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-γ agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-γ agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-γ agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

公开(公告)号：US20190071505A1

公开(公告)日：2019-03-07

申请号：US16125091

申请日：2018-09-07

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER

Inventor： Purunelloor A. Mathew ,  Stephen O. Mathew

IPC: C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K9/00 ,  A61K51/10

Abstract: Certain embodiments are directed to methods of treating LLT1 expressing cancer by administering to a subject having an LLT1 expressing cancer an LLT1 inhibitor.

公开(公告)号：US20170165200A1

公开(公告)日：2017-06-15

申请号：US15355318

申请日：2016-11-18

Applicant: University of North Texas Health Science Center

Inventor： Xiaowei DONG ,  Iok-Hou PANG

IPC: A61K9/127 ,  A61K47/24 ,  A61K47/28 ,  A61K38/17 ,  A61K31/337 ,  A61K47/26 ,  A61K47/10 ,  A61K47/12 ,  A61K38/18 ,  A61K47/22 ,  C12N15/113

CPC classification number: A61K9/1275 ,  A61K31/337 ,  A61K38/1709 ,  A61K38/185 ,  A61K47/10 ,  A61K47/12 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  C12N15/111 ,  C12N2310/11 ,  C12N2320/31 ,  C12N2320/32

Abstract: Described herein are nanoparticles comprising a mixture of a steroid, a phospholipid composition, an α-tocopheryl compound, and a therapeutic agent wherein the α-tocopheryl compound is presented on the surface of the nanoparticle. In some embodiments, the nanoparticles are useful for delivering a peptide or a protein. In some embodiments, the nanoparticles are formulated for ocular administration. In other embodiments, the nanoparticles are formulated to cross the blood brain barrier for the delivery of the therapeutic agents to the brain.